{
  "id": "5fe3130ca43ad3127800003e",
  "type": "factoid",
  "question": "Which disease is monitored in the BIOCURA cohort?",
  "ideal_answer": "Rheumatoid Arthritis (RA) is one of the diseases that is monitored in the BIOCURA cohort. There are other diseases that are monitored as well, such as breast cancer, ovarian cancer, and thyroid cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27631111",
    "http://www.ncbi.nlm.nih.gov/pubmed/27749223",
    "http://www.ncbi.nlm.nih.gov/pubmed/28650254",
    "http://www.ncbi.nlm.nih.gov/pubmed/27558398",
    "http://www.ncbi.nlm.nih.gov/pubmed/29808722"
  ],
  "snippets": [
    {
      "text": "In RA patients eligible for biological treatment included in the BiOCURA registry, 53 inflammatory proteins were measured using xMAP\u00ae technology.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28650254",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several studies have employed microarray-based profiling to predict response to tumor necrosis factor-alpha inhibitors (TNFi) in rheumatoid arthritis (RA); yet efforts to validate these targets have failed to show predictive abilities acceptable for clinical practice.METHODS: The eighty most extreme responders and nonresponders to TNFi therapy were selected from the observational BiOCURA cohort. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29808722",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the metabolomic profiling, lipids, oxylipins, and amines were measured in serum samples of RA patients from the observational BiOCURA cohort, before start of biological treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27631111",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In clinical practice, approximately one-third of patients with rheumatoid arthritis (RA) respond insufficiently to TNF-\u03b1 inhibitors (TNFis). The aim of the study was to explore the use of a metabolomics to identify predictors for the outcome of TNFi therapy, and study the metabolomic fingerprint in active RA irrespective of patients' response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27631111",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "From the observational BiOCURA cohort, 40 adalimumab- (ADA) and 40 etanercept- (ETN) treated patients were selected to enter the discovery cohort and baseline serum profiling on 758 miRNAs was performed. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27558398",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Despite the success of TNF-alpha inhibitor (TNFi) treatment in rheumatoid arthritis (RA), a substantial number of patients necessitate discontinuation. Prediction thereof would be clinically relevant and guide the decision whether to start TNFi treatment.METHODS: Data were used from the observational BiOCURA cohort, in which patients initiating biological treatment were enrolled and followed up for one year. I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27749223",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Several studies have employed microarray-based profiling to predict response to tumor necrosis factor-alpha inhibitors (TNFi) in rheumatoid arthritis (RA); yet efforts to validate these targets have failed to show predictive abilities acceptable for clinical practice",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29808722",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Rheumatoid Arthritis, RA"
}